Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller aims to make hysteroscopy safer and more comfortable

NCT ID NCT07713134

Symptom relief Sponsor: Tangshan Maternal and Child Health Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial compares a new painkiller called oliceridine to the standard drug sufentanil for women undergoing hysteroscopy, a procedure to look inside the uterus. The goal is to see if oliceridine provides effective pain control with fewer side effects like nausea or breathing problems. The study includes 225 women aged 18 to 60 who are in good health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oliceridine, a biased μ-opioid receptor agonist, compared with sufentanil
What this could lead to
If oliceridine works well, it could offer a safer alternative for pain relief during minor surgical procedures, with fewer side effects like nausea or breathing problems.
What could go wrong
This is a single trial with 225 participants, so results may not apply to everyone. Oliceridine is still experimental, and its safety and effectiveness compared to standard drugs are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

225 people

The number who actually took part.

Started

Aug 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. voluntary signing of the anesthesia informed consent form; 2. stable vital signs; 3. age between 18 and 60years; 4. American Society of Anesthesiologists (ASA) physical status I or II; and 5. body mass index (BMI) \<30 kg/m² Exclusion Criteria: 1. inability or unwillingness to sign the informed consent form; 2. known allergy to the study drug; 3. uncontrolled hypertension or diabetes mellitus; 4. significant central nervous system disease; 5. diagnosed psychiatric disorders; 6. use of anxiolytics, antidepressants, hypnotics, or sedatives within the past three months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Analgeisa are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pain agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Analgeisa Hysteroscopy

Contacts and locations

Locations

  • Tangshan Maternal and Child Health Hospital, Tangshan, Hebei 063000

    Tangshan, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.